COCO Stock Analysis: Vita Coco | NASDAQ
Beverages - Non-Alcoholic | NASDAQ, USA | Market Cap: 3.414m USD | 12M Return: 33.5% | US92846Q1076 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 74.6M
EPS Trend: 84.8%
Qual. Beats: 0
Rev. Trend: 94.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Vita Coco Company, Inc. is a New York-headquartered beverage company that develops, manufactures, markets, and distributes coconut water products under the Vita Coco brand across the United States, Canada, Europe, the Middle East, Africa, and the Asia Pacific. Its product portfolio spans coconut water, oil, and juice, along with adjacent offerings including Vita Coco Treats (a plant-based dairy alternative), Vita Coco Coconut MLK, PWR LIFT (a protein-infused fitness drink), and the Farmers Organic brand, while also supplying private-label products to retailers. Distribution is conducted through club, food, drug, mass, convenience, e-commerce, and foodservice channels. The company was originally incorporated in 2004 as All Market Inc., was renamed The Vita Coco Company, Inc. in September 2021, and trades on NASDAQ under the ticker COCO after its October 2021 IPO.
Operating within the Consumer Staples sector and the Soft Drinks & Non-alcoholic Beverages sub-industry, Vita Coco benefits from exposure to two durable consumer trends: the shift toward naturally hydrating, functional beverages and the broader mainstreaming of plant-based dairy alternatives, both of which support demand for its coconut-derived product range across retail and foodservice channels.
- Coconut input cost inflation pressures gross margins
- International expansion fuels double-digit revenue growth
- Private label competition intensifies in coconut water category
| Net Income: 109.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 15.50 > 1.0 |
| NWC/Revenue: 53.20% < 20% (prev 49.42%; Δ 3.78% < -1%) |
| CFO/TA 0.23 > 3% & CFO 131.7m > Net Income 109.5m |
| Net Debt (-252.1m) to EBITDA (143.9m): -1.75 < 3 |
| Current Ratio: 3.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.4m) vs 12m ago 1.25% < -2% |
| Gross Margin: 40.97% > 18% (prev 36.05%; Δ 4.92% > 0.5%) |
| Asset Turnover: 142.1% > 50% (prev 133.0%; Δ 9.09% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.66 (Total Current Assets 535.0m - Total Current Liabilities 159.4m) / Total Assets 572.9m |
| B: 0.54 (Retained Earnings 307.9m / Total Assets 572.9m) |
| C: 0.29 (EBIT TTM 142.2m / Avg Total Assets 497.0m) |
| D: 2.33 (Book Value of Equity 400.9m / Total Liabilities 172.0m) |
| Altman-Z'' = 10.42 = AAA |
| DSRI: 1.02 (Receivables 132.3m/102.6m, Revenue 706.0m/559.9m) |
| GMI: 0.88 (GM 36.05% / 40.97%) |
| AQI: 0.72 (AQ_t 0.03 / AQ_t-1 0.04) |
| SGI: 1.26 (Revenue 706.0m / 559.9m) |
| TATA: -0.04 (NI 109.5m - CFO 131.7m) / TA 572.9m) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of October 29, 2026, the stock is trading at USD 56.37 with a total of 952,365 shares traded. Over the past week, the price has changed by -11.23%, over one month by -2.24%, over three months by -18.99% and over the past year by +33.45%.
Current recommended Stop Loss: 48.60 (which is 13.8% or 2.5 ATR below the current price).
Vita Coco has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy COCO.
- StrongBuy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 79.1 | 40.3% |
P/E Trailing = 29.798
P/E Forward = 28.8184
P/S = 4.448
P/B = 8.3714
Revenue TTM = 706.0m USD
EBIT TTM = 142.2m USD
EBITDA TTM = 143.9m USD
Long Term Debt = 12.5m USD (estimated: total debt 14.1m - short term 1.54m)
Short Term Debt = 1.54m USD (from shortTermDebt, last quarter)
Debt = 26.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.5m
Net Debt = -252.1m USD (calculated: Debt 26.6m - CCE 278.6m)
Enterprise Value = 3.16b USD (3.41b + Debt 26.6m - CCE 278.6m)
Interest Coverage Ratio = unknown (Ebit TTM 142.2m / Interest Expense TTM 0.0)
EV/FCF = 25.41x (Enterprise Value 3.16b / FCF TTM 124.4m)
FCF Yield = 3.94% (FCF TTM 124.4m / Enterprise Value 3.16b)
FCF Margin = 17.63% (FCF TTM 124.4m / Revenue TTM 706.0m)
Net Margin = 15.50% (Net Income TTM 109.5m / Revenue TTM 706.0m)
Gross Margin = 40.97% ((Revenue TTM 706.0m - Cost of Revenue TTM 416.8m) / Revenue TTM)
Gross Margin QoQ = 48.72% (prev 39.68%)
Tobins Q-Ratio = 5.52 (Enterprise Value 3.16b / Total Assets 572.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 26.6m)
Taxrate = 23.05% (32.8m / 142.2m)
NOPAT = 109.5m (EBIT 142.2m * (1 - 23.05%))
Current Ratio = 3.36 (Total Current Assets 535.0m / Total Current Liabilities 159.4m)
Debt / Equity = 0.07 (Debt 26.6m / totalStockholderEquity, last quarter 400.9m)
Debt / EBITDA = -1.75 (Net Debt -252.1m / EBITDA 143.9m)
Debt / FCF = -2.03 (Net Debt -252.1m / FCF TTM 124.4m)
Total Stockholder Equity = 352.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.02% (Net Income 109.5m / Total Assets 572.9m)
RoE = 31.09% (Net Income TTM 109.5m / Total Stockholder Equity 352.1m)
RoCE = 39.01% (EBIT 142.2m / Capital Employed (Equity 352.1m + L.T.Debt 12.5m))
RoIC = 28.82% (NOPAT 109.5m / Invested Capital 379.8m)
WACC = 6.85% (E(3.41b)/V(3.44b) * Re(6.90%) + D(26.6m)/V(3.44b) * Rd(0.0%) * (1-Tc(0.23)))
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.82 | Cagr: 1.23%
[DCF] Terminal Value 77.97% ; FCFF base≈85.1m ; Y1≈97.6m ; Y5≈143.6m
[DCF] Fair Price = 41.71 (EV 2.16b - Net Debt -252.1m = Equity 2.41b / Shares 57.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.80 | EPS CAGR: 23.38% | SUE: 0.73 | # QB: 0
Revenue Correlation: 94.87 | Revenue CAGR: 14.53% | SUE: 0.45 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.55 | Chg30d=+0.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=2.06 | Chg30d=+1.72% | Revisions=+40% | GrowthEPS=+55.6% | GrowthRev=+34.0%
EPS next Year (2027-12-31): EPS=2.33 | Chg30d=-0.64% | Revisions=+40% | GrowthEPS=+12.6% | GrowthRev=+21.1%
[Analyst] Revisions Ratio: +62% (up=5, down=0)